CLDX

SEC source: 0001179110-21-011251 · edgar.xml · derivative · entry 4

Martin Samuel Bates · CIK 0001709024 · SVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,530

Underlying: Common Stock · 3,250 shares

Expires 2028-06-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001179110-21-011251 · edgar.xml · nonDerivative · entry 3

Martin Samuel Bates · CIK 0001709024 · SVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,378

F1 · kind: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on August 12, 2021.

F1 · shares: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on August 12, 2021.

SEC source: 0001179110-21-011251 · edgar.xml · nonDerivative · entry 2

Martin Samuel Bates · CIK 0001709024 · SVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,878

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-21-011251 · edgar.xml · nonDerivative · entry 1

Martin Samuel Bates · CIK 0001709024 · SVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,128

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-21-010820 · edgar.xml · derivative · entry 5

Cavanaugh Sarah · CIK 0001709113 · SVP of Corp Affairs & Admin.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,534

Underlying: Common Stock · 5,466 shares

Expires 2030-06-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001179110-21-010820 · edgar.xml · derivative · entry 4

Cavanaugh Sarah · CIK 0001709113 · SVP of Corp Affairs & Admin.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,458

Underlying: Common Stock · 1,857 shares

Expires 2028-06-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001179110-21-010820 · edgar.xml · nonDerivative · entry 3

Cavanaugh Sarah · CIK 0001709113 · SVP of Corp Affairs & Admin.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 408

F1 · kind: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 10, 2021.

F1 · shares: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 10, 2021.

SEC source: 0001179110-21-010820 · edgar.xml · nonDerivative · entry 2

Cavanaugh Sarah · CIK 0001709113 · SVP of Corp Affairs & Admin.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,731

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-21-010820 · edgar.xml · nonDerivative · entry 1

Cavanaugh Sarah · CIK 0001709113 · SVP of Corp Affairs & Admin.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,265

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-21-010819 · edgar.xml · derivative · entry 3

Crowley Elizabeth · CIK 0001681854 · Sr. VP &CPDO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 4,000 shares

Expires 2028-06-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 300,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.

F3 · derivative.exercise_date: 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

F1 · balance_after: On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 300,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.

SEC source: 0001179110-21-010819 · edgar.xml · nonDerivative · entry 2

Crowley Elizabeth · CIK 0001681854 · Sr. VP &CPDO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,726

F2 · kind: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 15, 2021.

F2 · shares: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 15, 2021.

SEC source: 0001179110-21-010819 · edgar.xml · nonDerivative · entry 1

Crowley Elizabeth · CIK 0001681854 · Sr. VP &CPDO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,726

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 300,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.

F1 · price: On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 300,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.

SEC source: 0001179110-21-010818 · edgar.xml · derivative · entry 3

Heath-Chiozzi Margo · CIK 0001718112 · SVP of Regulatory Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,800

Underlying: Common Stock · 600 shares

Expires 2029-06-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 25 % vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001179110-21-010818 · edgar.xml · nonDerivative · entry 2

Heath-Chiozzi Margo · CIK 0001718112 · SVP of Regulatory Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,247

F1 · kind: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on August 13, 2021.

F1 · shares: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on August 13, 2021.

SEC source: 0001179110-21-010818 · edgar.xml · nonDerivative · entry 1

Heath-Chiozzi Margo · CIK 0001718112 · SVP of Regulatory Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,847

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-21-010208 · edgar.xml · derivative · entry 6

Martin Samuel Bates · CIK 0001709024 · SVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,171

Underlying: Common Stock · 3,750 shares

Expires 2029-06-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001179110-21-010208 · edgar.xml · derivative · entry 5

Martin Samuel Bates · CIK 0001709024 · SVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,780

Underlying: Common Stock · 3,250 shares

Expires 2028-06-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001179110-21-010208 · edgar.xml · nonDerivative · entry 4

Martin Samuel Bates · CIK 0001709024 · SVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,878

F1 · kind: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on August 12, 2021.

F1 · shares: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on August 12, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.11 to $42.77 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001179110-21-010208 · edgar.xml · nonDerivative · entry 3

Martin Samuel Bates · CIK 0001709024 · SVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,926

F1 · kind: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on August 12, 2021.

F1 · shares: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on August 12, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.29 to $44.24 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001179110-21-010208 · edgar.xml · nonDerivative · entry 2

Martin Samuel Bates · CIK 0001709024 · SVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,378

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-21-010208 · edgar.xml · nonDerivative · entry 1

Martin Samuel Bates · CIK 0001709024 · SVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,628

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-21-010165 · edgar.xml · derivative · entry 3

Young Diane C. · CIK 0001648010 · SVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,400

Underlying: Common Stock · 4,600 shares

Expires 2030-06-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001179110-21-010165 · edgar.xml · nonDerivative · entry 2

Young Diane C. · CIK 0001648010 · SVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,115

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.6400 to $43.2000 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001179110-21-010165 · edgar.xml · nonDerivative · entry 1

Young Diane C. · CIK 0001648010 · SVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,715

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-21-009818 · edgar.xml · derivative · entry 7

Cavanaugh Sarah · CIK 0001709113 · SVP of Corp Affairs & Admin.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,062

Underlying: Common Stock · 938 shares

Expires 2029-06-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001179110-21-009818 · edgar.xml · derivative · entry 6

Cavanaugh Sarah · CIK 0001709113 · SVP of Corp Affairs & Admin.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,315

Underlying: Common Stock · 5,018 shares

Expires 2028-06-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: This option was previously reported as covering 275,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.

F2 · shares: This option was previously reported as covering 275,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.

F7 · derivative.exercise_date: 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

F2 · balance_after: This option was previously reported as covering 275,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.

SEC source: 0001179110-21-009818 · edgar.xml · nonDerivative · entry 5

Cavanaugh Sarah · CIK 0001709113 · SVP of Corp Affairs & Admin.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 408

F3 · kind: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 10, 2021.

F3 · shares: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 10, 2021.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.180 to $41.990 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001179110-21-009818 · edgar.xml · nonDerivative · entry 4

Cavanaugh Sarah · CIK 0001709113 · SVP of Corp Affairs & Admin.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,528

F3 · kind: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 10, 2021.

F3 · shares: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 10, 2021.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.580 to $43.360 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001179110-21-009818 · edgar.xml · nonDerivative · entry 3

Cavanaugh Sarah · CIK 0001709113 · SVP of Corp Affairs & Admin.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,429

F3 · kind: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 10, 2021.

F3 · shares: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 10, 2021.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.710 to $44.420 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001179110-21-009818 · edgar.xml · nonDerivative · entry 2

Cavanaugh Sarah · CIK 0001709113 · SVP of Corp Affairs & Admin.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,731

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-21-009818 · edgar.xml · nonDerivative · entry 1

Cavanaugh Sarah · CIK 0001709113 · SVP of Corp Affairs & Admin.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,793

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · shares: This option was previously reported as covering 275,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.

F2 · price: This option was previously reported as covering 275,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.

F1 · balance_after: Includes 408 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan on June 30, 2021. On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

SEC source: 0001179110-21-009816 · edgar.xml · derivative · entry 5

Crowley Elizabeth · CIK 0001681854 · Sr. VP &CPDO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,445

Underlying: Common Stock · 8,555 shares

Expires 2029-06-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001179110-21-009816 · edgar.xml · nonDerivative · entry 4

Crowley Elizabeth · CIK 0001681854 · Sr. VP &CPDO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,726

F1 · kind: On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

F2 · shares: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 15, 2021.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.400 to $41.990 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001179110-21-009816 · edgar.xml · nonDerivative · entry 3

Crowley Elizabeth · CIK 0001681854 · Sr. VP &CPDO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,915

F1 · kind: On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

F2 · shares: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 15, 2021.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.580 to $43.360 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001179110-21-009816 · edgar.xml · nonDerivative · entry 2

Crowley Elizabeth · CIK 0001681854 · Sr. VP &CPDO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,515

F1 · kind: On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

F2 · shares: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 15, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.710 to $44.420 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001179110-21-009816 · edgar.xml · nonDerivative · entry 1

Crowley Elizabeth · CIK 0001681854 · Sr. VP &CPDO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,043

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

SEC source: 0001179110-21-009815 · edgar.xml · derivative · entry 3

Heath-Chiozzi Margo · CIK 0001718112 · SVP of Regulatory Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,400

Underlying: Common Stock · 600 shares

Expires 2029-06-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 25 % vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001179110-21-009815 · edgar.xml · nonDerivative · entry 2

Heath-Chiozzi Margo · CIK 0001718112 · SVP of Regulatory Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,247

F1 · kind: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on August 13, 2021.

F1 · shares: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on August 13, 2021.

SEC source: 0001179110-21-009815 · edgar.xml · nonDerivative · entry 1

Heath-Chiozzi Margo · CIK 0001718112 · SVP of Regulatory Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,847

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-21-008164 · edgar.xml · derivative · entry 2

Heath-Chiozzi Margo · CIK 0001718112 · SVP of Regulatory Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,332

Underlying: Common Stock · 10,000 shares

Expires 2028-06-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: This option was previously reported as covering 275,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.

F3 · derivative.exercise_date: 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters

F2 · balance_after: This option was previously reported as covering 275,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.

SEC source: 0001179110-21-008164 · edgar.xml · nonDerivative · entry 1

Heath-Chiozzi Margo · CIK 0001718112 · SVP of Regulatory Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,247

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: This option was previously reported as covering 275,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.

F1 · balance_after: Includes 247 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan. On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

SEC source: 0001179110-21-008163 · edgar.xml · nonDerivative · entry 1

Jimenez Freddy A. · CIK 0001838114 · SVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 430

SEC source: 0001179110-21-008140 · edgar.xml · derivative · entry 6

Martin Samuel Bates · CIK 0001709024 · SVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,921

Underlying: Common Stock · 11,079 shares

Expires 2029-06-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001179110-21-008140 · edgar.xml · derivative · entry 5

Martin Samuel Bates · CIK 0001709024 · SVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,030

Underlying: Common Stock · 10,302 shares

Expires 2028-06-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: This option was previously reported as covering 395,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.

F4 · derivative.exercise_date: 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

F2 · balance_after: This option was previously reported as covering 395,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.

SEC source: 0001179110-21-008140 · edgar.xml · nonDerivative · entry 4

Martin Samuel Bates · CIK 0001709024 · SVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,378

F3 · kind: Represents shares sold upon exercise of option in payment of exercise price pursuant to broker-assisted cashless exercise transaction.

F3 · shares: Represents shares sold upon exercise of option in payment of exercise price pursuant to broker-assisted cashless exercise transaction.

SEC source: 0001179110-21-008140 · edgar.xml · nonDerivative · entry 3

Martin Samuel Bates · CIK 0001709024 · SVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,060

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-21-008140 · edgar.xml · nonDerivative · entry 2

Martin Samuel Bates · CIK 0001709024 · SVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,981

F3 · kind: Represents shares sold upon exercise of option in payment of exercise price pursuant to broker-assisted cashless exercise transaction.

F3 · shares: Represents shares sold upon exercise of option in payment of exercise price pursuant to broker-assisted cashless exercise transaction.

F1 · balance_after: On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

SEC source: 0001179110-21-008140 · edgar.xml · nonDerivative · entry 1

Martin Samuel Bates · CIK 0001709024 · SVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,037

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: This option was previously reported as covering 395,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.

F1 · balance_after: On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

SEC source: 0001179110-21-008010 · edgar.xml · derivative · entry 2

Marucci Anthony S · CIK 0001429933 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,537 shares

Expires 2021-08-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: This option was previously reported as covering 180,400 shares at an exercise price of $2.80 per share, but has been adjusted to reflect the Reverse Stock Split. The remaining 8,488 shares of common stock underlying the option expired on August 5, 2021.

F3 · derivative.exercise_date: As of August 5, 2015, the option is fully vested.

F2 · balance_after: This option was previously reported as covering 180,400 shares at an exercise price of $2.80 per share, but has been adjusted to reflect the Reverse Stock Split. The remaining 8,488 shares of common stock underlying the option expired on August 5, 2021.

SEC source: 0001179110-21-008010 · edgar.xml · nonDerivative · entry 1

Marucci Anthony S · CIK 0001429933 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,231

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: This option was previously reported as covering 180,400 shares at an exercise price of $2.80 per share, but has been adjusted to reflect the Reverse Stock Split. The remaining 8,488 shares of common stock underlying the option expired on August 5, 2021.

F1 · balance_after: Includes 4,256 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Option Plan. On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.